Holen Sie sich die Stockscreener-App
0.5762
6.19%
0.0301
Schlusskurs vom Vortag:
$0.5461
Offen:
$0.51
24-Stunden-Volumen:
1.82M
Relative Volume:
0.09
Marktkapitalisierung:
$28.54M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-1.71%
1M Leistung:
+16.05%
6M Leistung:
-64.85%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.5079
$0.5801
1-Wochen-Bereich:
$0.43
$0.65
52-Wochen-Spanne:
$0.215
$2.10
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
Firmenname
Aspire Biopharma Holdings Inc
Sektor
Branche
Telefon
561-704-8527
Adresse
194 CANDELARO DRIVE, #233, HUMACAO
Vergleichen Sie ASBP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
0.5762 | 29.22M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.23 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
579.32 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.37 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
685.40 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
314.03 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Aspire Biopharma Holdings Inc Aktie (ASBP) Neueste Nachrichten
Aspire Biopharma Holdings, Inc. Building a Base Near Support2025 Retail Activity & Weekly Setup with High ROI Potential - thegnnews.com
Aspire Biopharma Plummets 22.7%: E-Commerce Launch Volatility and Technical Divergence Spark Turbulence - AInvest
Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - BioSpace
Penny Stocks on the Move: Today’s Top Gainers and Biggest Decliners - AInvest
Aspire Shares Are Trading Higher Monday: What's Going On? - Benzinga
Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August - Benzinga
Aspire Biopharma Holdings shares surge 67.69% intraday after positive clinical trial results for sublingual aspirin product. - AInvest
US Stocks Mixed; Riskified Shares Dip After Q2 Results - Benzinga
Breakthrough Heart Attack Treatment: Sublingual Aspirin Shows Superior Results in Aspire Biopharma Trial - Stock Titan
Aspire Biopharma names new executive chair - MSN
Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World - Lubbock Avalanche-Journal
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20 - Miami Herald
Aspire Biopharma to Present at Sidoti Virtual Investor Conference - AInvest
Aspire Biopharma’s BUZZ BOMB Shows Promising Initial Feedback - MSN
Aspire Biopharma Holdings, Inc. SEC 10-Q Report - TradingView
New Pre-Workout BUZZ BOMB Hits Market With Instant-Acting Sublingual Technology - Stock Titan
Aspire Biopharma Holdings, Inc. Announces CEO Transition - Lubbock Avalanche-Journal
Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement - Petoskey News-Review
Riding the Waves: A Guide to Investing in ASBP Stock - investchronicle.com
Aspire Biopharma Holdings, Inc. shares rise 4.06% after-hours following Ultragenyx Pharmaceutical Inc. Q2 2025 earnings call. - AInvest
Aspire Biopharma Holdings, Inc. shares rise 2.10% after-hours after unveiling e-commerce platform and launching BUZZ BOMB supplement. - AInvest
What catalysts could drive Aspire Biopharma Holdings Inc. stock higher in 2025Expert Picks Tracker For Beginners - Jammu Links News
Game-Changing Pre-Workout Supplement Delivers Instant Energy Without Water MixingBUZZ BOMB Hits Market - Stock Titan
Why is Aspire Biopharma Holdings Inc. Equity Warrant stock attracting strong analyst attentionDaily Trading Insights With High Returns - Jammu Links News
Aspire Biopharma Announces Leadership Reshuffle Amid Resignations - msn.com
What makes Aspire Biopharma Holdings Inc. Equity Warrant stock price move sharplyPost Market Outlook For Smart Trading - Jammu Links News
Aspire Biopharma Leadership Shakeup: Chairman Takes CEO Role Amid Board Restructuring - Stock Titan
Aspire Biopharma CEO Out After Less Than Two Months, Two Directors Resign - 富途牛牛
ASBP CEO & Audit Chair Resign; Former CEO Returns as Interim | PWUPU SEC FilingForm 8-K - Stock Titan
Uncorrelated Capital Launches with $53M in Funding for Litigation Finance - The Arizona Republic
What catalysts could drive Aspire Biopharma Holdings Inc. Equity Warrant stock higher in 2025Capitalize on fast-moving stock trends - Jammu Links News
How many analysts rate Aspire Biopharma Holdings Inc. as a “Buy”Consistent triple returns - Jammu Links News
Why is Aspire Biopharma Holdings Inc. stock attracting strong analyst attentionSkyrocketing investment returns - Jammu Links News
What is the dividend policy of Aspire Biopharma Holdings Inc. stockConsistent triple-digit returns - Jammu Links News
How does Aspire Biopharma Holdings Inc. compare to its industry peersCapitalize on fast-growing stocks today - Jammu Links News
What is the risk reward ratio of investing in Aspire Biopharma Holdings Inc. stockUnlock powerful trading tools for investors - jammulinksnews.com
Is it the right time to buy Aspire Biopharma Holdings Inc. Equity Warrant stockCapitalize on emerging market trends - Jammu Links News
Finanzdaten der Aspire Biopharma Holdings Inc-Aktie (ASBP)
Es liegen keine Finanzdaten für Aspire Biopharma Holdings Inc (ASBP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):